CN110088088A - {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 - Google Patents

{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 Download PDF

Info

Publication number
CN110088088A
CN110088088A CN201780075695.1A CN201780075695A CN110088088A CN 110088088 A CN110088088 A CN 110088088A CN 201780075695 A CN201780075695 A CN 201780075695A CN 110088088 A CN110088088 A CN 110088088A
Authority
CN
China
Prior art keywords
crystal form
preparation
chlorphenyl
pyridone
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780075695.1A
Other languages
English (en)
Other versions
CN110088088B (zh
Inventor
陈敏华
张炎锋
邹坡
王金秋
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmaceutical Suzhou Co Ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Publication of CN110088088A publication Critical patent/CN110088088A/zh
Application granted granted Critical
Publication of CN110088088B publication Critical patent/CN110088088B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本发明涉及{[5‑(3‑氯苯基)‑3‑羟基吡啶‑2‑羰基]氨基}乙酸的新晶型及其制备方法和用途。本发明制备得到的{[5‑(3‑氯苯基)‑3‑羟基吡啶‑2‑羰基]氨基}乙酸的晶型CS1、晶型CS2、晶型CS8，可用于制备治疗贫血症药物制剂，为含{[5‑(3‑氯苯基)‑3‑羟基吡啶‑2‑羰基]氨基}乙酸的药物制剂的制备提供了新的选择，对于药物开发具有非常重要的价值。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201780075695.1A 2016-12-13 2017-12-13 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 Active CN110088088B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611148362 2016-12-13
CN2016111483620 2016-12-13
PCT/CN2017/115909 WO2018108101A1 (zh) 2016-12-13 2017-12-13 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN110088088A true CN110088088A (zh) 2019-08-02
CN110088088B CN110088088B (zh) 2022-03-29

Family

ID=62558034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075695.1A Active CN110088088B (zh) 2016-12-13 2017-12-13 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法

Country Status (10)

Country Link
US (1) US10703724B2 (zh)
EP (2) EP3763703A3 (zh)
JP (1) JP2020500925A (zh)
KR (1) KR20190093651A (zh)
CN (1) CN110088088B (zh)
AU (1) AU2017376517B2 (zh)
CA (1) CA3046377C (zh)
ES (1) ES2831863T3 (zh)
MX (1) MX2019006883A (zh)
WO (1) WO2018108101A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886896C (en) 2012-10-12 2020-03-10 Blue Sky Mines Ltd. Methods of and systems for treating incinerated waste
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
WO2020075199A1 (en) * 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
EP3887356B1 (en) 2018-11-28 2023-08-02 Sandoz AG Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
IT202000014116A1 (it) 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
GB202011431D0 (en) 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2022048613A1 (zh) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506149A (zh) * 2006-06-26 2009-08-12 宝洁公司 脯氨酰羟化酶抑制剂及使用方法
WO2012170377A1 (en) * 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
CN105916502A (zh) * 2013-11-15 2016-08-31 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
WO2016153996A1 (en) * 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506149A (zh) * 2006-06-26 2009-08-12 宝洁公司 脯氨酰羟化酶抑制剂及使用方法
WO2012170377A1 (en) * 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
CN105916502A (zh) * 2013-11-15 2016-08-31 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
WO2016153996A1 (en) * 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors

Also Published As

Publication number Publication date
CN110088088B (zh) 2022-03-29
US20200095203A1 (en) 2020-03-26
EP3549932B1 (en) 2020-09-30
EP3763703A2 (en) 2021-01-13
AU2017376517B2 (en) 2021-03-25
AU2017376517A1 (en) 2019-07-25
EP3549932A1 (en) 2019-10-09
ES2831863T3 (es) 2021-06-09
US10703724B2 (en) 2020-07-07
CA3046377A1 (en) 2018-06-21
WO2018108101A1 (zh) 2018-06-21
CA3046377C (en) 2021-03-30
KR20190093651A (ko) 2019-08-09
JP2020500925A (ja) 2020-01-16
EP3549932A4 (en) 2020-01-01
MX2019006883A (es) 2019-10-21
EP3763703A3 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
CN110088088A (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
CN110128356A (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
CN109641851A (zh) 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
CN107108603B (zh) 芒果苷-6-o-小檗碱盐及其制备方法与用途
EP3279201B1 (en) Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
CN106831819A (zh) 德罗格韦钠盐的晶型及其制备方法
CN110446705A (zh) (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式
CN110049981A (zh) 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途
CN105801568B (zh) 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
CN104540822B (zh) 达拉菲尼甲磺酸盐的晶型及其制备方法
CN110156700A (zh) 吉非替尼与水杨酸共晶体
CN104557870B (zh) 一种吡啶胺化合物的富马酸盐
CN111454221B (zh) 一种吉非替尼和布美他尼药物共晶体及其制备方法
CN106748996A (zh) 一种甲苯磺酸索拉非尼晶型化合物及其制备方法
TW202104216A (zh) Plk4抑制劑之結晶型
CN110036003A (zh) Ap26113的新晶型及其制备方法
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
CN113234064B (zh) 一种替加氟衍生物及其制备方法与应用
CN109153677A (zh) Plx3397的盐酸盐晶型及其制备方法和用途
CN108299412A (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
JP5589097B2 (ja) ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN112119062A (zh) 化合物晶型、其制备方法、药物组合物以及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant